ADC Therapeutics SA (NYSE:ADCT) Stock Rated “Hold” by Sell-Side Analysts

ADC Therapeutics SA (NYSE:ADCT) has been given a consensus rating of “Hold” by the six analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $5.00.

A number of analysts have recently commented on ADCT shares. Wall Street Zen upgraded ADC Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Guggenheim decreased their price objective on ADC Therapeutics to $5.00 and set a “buy” rating for the company in a report on Monday, August 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Thursday, October 15th.

ADC Therapeutics Trading Up 2.3%

ADCT opened at $1.52 on Friday. The stock has a market capitalization of $194.70 million, a P/E ratio of -2.31 and a beta of 1.86. ADC Therapeutics has a 12 month low of $0.78 and a 12 month high of $4.98. The firm’s fifty day simple moving average is $1.30 and its 200 day simple moving average is $2.48.

ADC Therapeutics (NYSE:ADCT) last announced its earnings results on Thursday, August 13th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.11. The company had revenue of $19.25 million during the quarter, compared to analyst estimates of $18.89 million. On average, equities research analysts predict that ADC Therapeutics will post -0.80 EPS for the current fiscal year.

Hedge Funds Weigh In On ADC Therapeutics

Hedge funds have recently made changes to their positions in the business. AXQ Capital LP acquired a new stake in shares of ADC Therapeutics in the second quarter valued at approximately $29,000. R Squared Ltd bought a new stake in shares of ADC Therapeutics in the first quarter worth $38,000. Quantinno Capital Management LP lifted its position in shares of ADC Therapeutics by 36.0% in the first quarter. Quantinno Capital Management LP now owns 14,719 shares of the company’s stock worth $55,000 after purchasing an additional 3,894 shares in the last quarter. Revolve Wealth Partners LLC acquired a new position in ADC Therapeutics during the second quarter worth $107,000. Finally, Sei Investments Co. boosted its holdings in ADC Therapeutics by 45.6% during the first quarter. Sei Investments Co. now owns 33,461 shares of the company’s stock worth $125,000 after purchasing an additional 10,472 shares during the last quarter. 41.10% of the stock is owned by institutional investors.

About ADC Therapeutics

ADC Therapeutics SA (NYSE: ADCT) is a biotechnology company focused on developing and commercializing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC platform is designed to combine monoclonal antibodies that target specific tumor-associated antigens with potent cytotoxic payloads, with the goal of selectively delivering treatment to cancer cells while limiting exposure to healthy tissue.

The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed against the CD19 antigen.